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was increasing and 10 years since the WHO declared
tuberculosis to be a global emergency (1). Yet so far only
one completely new therapeutic option for tuberculosis has
been undergoing trials: Mycobacterium vaccae (2). At
approximately the same time as tuberculosis was increasing
the relatively new threat of multi-drug-resistant tuberculosis
(tuberculosis resistant to at least isoniazid and rifampicin:
MDRTB) began to appear (3). Five years earlier a virtually
new disease emerged: AIDS. Now the combination of AIDS
and MDRTB threatens the world with its most serious
disease combination since tuberculosis began its modern
pandemic in industrial Europe some 200 years ago.
In the past two decades the contrast between the
development of new drugs against HIV and tuberculosis
has been striking. For the former we have at least 20 new
compounds, with more being produced every year; for the
latter, precisely none. To add insult to injury the media
supported by politicians and pop idols are bellowing for
pharmaceutical companies to reduce the cost of HAARTs.
But where were these voices in the 1970s campaigning for
cheaper rifampicin so that tuberculosis could be brought
under control in Africa and poorer parts of Asia before the
advent of AIDS came to break apart the existing fragile
healthcare structures?
The hypocrisy is easily explained by the perception that
AIDS is a rich man’s disease, and therefore forms a ready
market for pharmaceutical products, while TB is the poor
man’s. But in this respect public perception lead by an ill-
informed media machine is wrong. AIDS is undoubtedly a
poor man’s disease, as the orphans of central and Southern
Africa testify, while tuberculosis is increasing in many
developed countries. In the U.K. cases increased by 10% in
the year 2000 and more than half of TB cases are now born
in the developing world (4).
Interestingly, some of those individuals who have made
the most out of our current world economic system are
belatedly funding some aspects of tuberculosis control (5,6).
In the meantime investment by pharmaceutical companies
into anti-tuberculosis drugs remains derisory.
With this background it is encouraging to find that
Professor Stanford and others have not given up hope in
the one new therapeutic option we have on trial:M. vaccae.
The theory behind the possible therapeutic benefit to the
human immune response to M. vaccae seems sound. The
switch from a Th2 to a Th1 response by the use of
M. vaccae as an adjuvent to standard treatment has been
well demonstrated (7). Early non-randomized trials of the0954-6111/01/060435+02 $35?00/0vaccine appeared to be encouraging (8). The first small
controlled trials gave some cause for optimism (9,10), but
the results of a larger randomized control trial with over
170 patients in each arm, showed no benefit when
M. vaccae immunotherapy was added to standard anti-
tuberculosis chemotherapy in patients with fully drug
susceptible bacteria (11).
So, M. vaccae could not improve on optimal chemother-
apy in full drug-susceptible disease. It is unfortunately not
going to provide us with the means to shorten the standard
regimens to less than 6 months, a factor which would have
been so important in improving compliance and lowering
the cost of treatment.
But there are other important areas for investigation into
the possible ecacy of M. vaccae in the therapy of
mycobacterial disease, specifically against MDRTB and
environmental mycobacteria. In this issue of Respiratory
Medicine preliminary results of studies of the ecacy of
M. vaccae on MDRTB are published (12). As the authors
rightly say this series of pilot studies have weaknesses, not
least the fact that there were no placebo controls. Although
is shows thatM. vaccae may be effective and is certainly not
harmful, no true claim for its ecacy can be made from this
publication. Nevertheless, the journal is right to publish
these findings as a preliminary publication. There are good
precedents for so doing, especially where TB is concerned
(13). It is hoped that it may stimulate suitable funding for
further randomized trials, although the diculties of
carrying out such trials in MDRTB patients are many
and varied.
In the absence of realistic levels of investment into
research for new drugs for tuberculosis,M. vaccae seems to
be the only hope on the horizon. M. vaccae may offer new
hope for MDRTB but the question mark must remain for
the time being.
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